Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2021

According to the recently published report 'Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2021'; Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) – Glial -derived neurotrophic factor is a member of the cysteine-knot superfamily of growth factors. It promotes the survival and differentiation of dopaminergic neurons and was able to prevent apoptosis of motor neurons. The mature form of the protein is a ligand for the product of the RET (rearranged during transfection) protooncogene.

The report 'Glial Cell Line Derived Neurotrophic Factor – Drugs In Development, 2021' outlays comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 1 and 10 respectively. Similarly, the universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Ophthalmology and Cardiovascular which include indications Parkinson's Disease, Amyotrophic Lateral Sclerosis, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neuropathic Pain (Neuralgia), Glaucoma, Ischemic Stroke, Keratitis, Keratoconjunctivitis Sicca (Dry Eye), Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), Neurodegenerative Diseases, Peripheral Nerve Injury, Radiculopathy, Retinal Degeneration and Retinitis Pigmentosa (Retinitis).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)

– The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Asklepios BioPharmaceutical Inc

Biogen Inc

Copernicus Therapeutics Inc

Eli Lilly and Co

GlaxoSmithKline Plc

Junaxo Inc

Kai Nuo Bio Sci Co Ltd

Kolon Life Science Inc

Lauren Sciences LLC

Neuroptika Inc

Stem Cell Medicine Ltd

Treeway BV

UniQure NV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Overview

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development

Asklepios BioPharmaceutical Inc

Biogen Inc

Copernicus Therapeutics Inc

Eli Lilly and Co

GlaxoSmithKline Plc

Junaxo Inc

Kai Nuo Bio Sci Co Ltd

Kolon Life Science Inc

Lauren Sciences LLC

Neuroptika Inc

Stem Cell Medicine Ltd

Treeway BV

UniQure NV

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles

AMT-090 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Activate GDNF for Brain Ischemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis and Retinitis Pigmentosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GDNF for Multiple System Atrophy and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate GDNF for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-812 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KLS-2031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAUR-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAUR-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRO-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Activate GDNF for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

smilagenin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate BDNF, GDNF, IGF1 and VEGF for Peripheral Nerve Injury and Neuropathic Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TW-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Products

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Product Development Milestones

Featured News & Press Releases

Jun 18, 2021: CIRM Board approves new clinical trial for ALS

Aug 17, 2020: Neuroptika completes enrollment in phase 2 clinical trial for Dry Eye Disease

Apr 27, 2020: Kolon Life Sciences launches follow-up pipeline to administer the first patient in the US

Jan 17, 2020: Neuroptika enrols first patient for dry eye disease trial

Apr 30, 2019: Neuroptika announces positive data from NRO-1 phase 1 clinical trial

Mar 11, 2019: Kolon gets FDA nod for testing gene therapy for neuropathic pain

Dec 26, 2018: Neuroptika, Spun Out from Senju Pharmaceutical launches to develop novel regenerative treatment

Dec 26, 2018: Neuroptika, spun out from Senju Pharmaceutical launches to develop novel regenerative treatment

Oct 20, 2016: Cedars-Sinai Receives Approval to Test Novel Combined Stem Cell and Gene Therapy for ALS Patients

Apr 19, 2016: Lauren Sciences awarded second grant for LAUR-301 from The ALS Association

Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane

Feb 18, 2013: Phytopharm Announces Results From Parkinson’s Disease Clinical Trial Of Cogane

Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis

Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson’s Disease

Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Asklepios BioPharmaceutical Inc, 2021

Pipeline by Biogen Inc, 2021

Pipeline by Copernicus Therapeutics Inc, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by GlaxoSmithKline Plc, 2021

Pipeline by Junaxo Inc, 2021

Pipeline by Kai Nuo Bio Sci Co Ltd, 2021

Pipeline by Kolon Life Science Inc, 2021

Pipeline by Lauren Sciences LLC, 2021

Pipeline by Neuroptika Inc, 2021

Pipeline by Stem Cell Medicine Ltd, 2021

Pipeline by Treeway BV, 2021

Pipeline by UniQure NV, 2021

Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports